Biohaven (BHVN) Operating Income (2021 - 2026)
Biohaven (BHVN) posted Operating Income of -$130.4 million for Q1 2026, up 8.62% sequentially from -$142.7 million in Q4 2025, and up 41.13% YoY from -$92.4 million in Q1 2025.
Biohaven (BHVN) Operating Income (2021 - 2026) Analysis & Trends
Biohaven has reported Operating Income for 6 years, with the latest figure at -$130.4 million in Q1 2026.
- Quarterly Operating Income rose 41.13% year-over-year to -$130.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$654.2 million (up 29.15% YoY) and the FY2025 annual result came in at -$745.4 million, up 15.79% from the prior year.
- Operating Income improved to -$130.4 million in Q1 2026 per BHVN's latest filing, from -$142.7 million in the prior quarter.
- Over five years, Operating Income peaked at -$67.6 million in Q3 2022 and troughed at -$333.8 million in Q2 2024.
- A 5-year average of -$162.6 million and a median of -$169.4 million in 2025 frame the typical range for Operating Income.
- The sharpest annual moves came in 2022 and 2023: Operating Income slumped 319.42% in 2022, then surged 52.31% in 2023.
- Over 5 years, Operating Income stood at -$213.4 million in 2022, then rose by 27.97% to -$153.7 million in 2023, then fell by 23.56% to -$189.9 million in 2024, then advanced by 24.85% to -$142.7 million in 2025, then rose by 8.62% to -$130.4 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered -$130.4 million, -$142.7 million, and -$169.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Biohaven | 2.21 Bn | 1.94 Bn | - | -124.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -124.90 Mn |
| Mar 31, 2026 | -130.43 Mn |
| Dec 31, 2025 | -142.73 Mn |
| Sep 30, 2025 | -169.38 Mn |
| Jun 30, 2025 | -211.70 Mn |
| Mar 31, 2025 | -221.56 Mn |
| Dec 31, 2024 | -189.93 Mn |
| Sep 30, 2024 | -178.17 Mn |
| Jun 30, 2024 | -333.77 Mn |
| Mar 31, 2024 | -183.24 Mn |
| Dec 31, 2023 | -153.71 Mn |
| Sep 30, 2023 | -110.55 Mn |
| Jun 30, 2023 | -94.01 Mn |
| Mar 31, 2023 | -77.78 Mn |
| Dec 31, 2022 | -213.41 Mn |
| Sep 30, 2022 | -67.64 Mn |
| Jun 30, 2022 | -197.11 Mn |
| Mar 31, 2022 | -89.77 Mn |
| Dec 31, 2021 | -50.88 Mn |
| Sep 30, 2021 | -55.49 Mn |